AREDS and Genetic Risk: A Practical Clinical Approach to AMD La

AREDS and Genetic Risk: A Practical Clinical Approach to AMD La

|
AREDS-AMD AND GENETIC TESTING AREDS-DMLA ET LES TESTS GÉNÉTIQUES
By/Par Shaun Golemba, O.D.
AREDS and Genetic Risk:
A Practical Clinical Approach to AMD
La formulation AREDS et le risque génétique
Here is the full list of references for this article:
Voici la liste intégrale des références de cet article :
1. Topol, E. 2012. The Creative Destruction of Medicine. New
York, NY: Basic Books.
6. Kustra, R. A. A review of AREDS Report #38.
2. Klein, RJ, et al. 2005. Complement Factor H Polymorphism
in Age-Related Macular Degeneration. Science.
308(5720):385-389.
8.http://news.nationalpost.com/news/canada/canadian-firmand-u-s-research-agency-in-heated-battle-over-safety-ofanti-blindness-pill
3. Klein ML, Francis PJ, Rosner B, et al. 2008. CFH
and LOC387715/ARMS2 Genotypes and Treatment
with Antioxidants and Zinc for Age-Related Macular
Degeneration. Ophthalmology. 115:1019–25.
9. 2001. Age-Related Eye Disease Study Research Group. A
Randomized, Placebo-Controlled Clinical Trial of High Dose
Supplementation with Vitamins C and E, Beta Carotene, and
Zinc for Age-Related Macular Degeneration and Vision Loss:
AREDS Report no. 8. Arch Ophthalmol. 119:1417–36.
4. Awh CC, Hawkin S, Zanke BW. 2015. Treatment Response
to Antioxidants and Zinc Based on CFH and ARMS2 Genetic
Risk Allele Number in the Age-Related Eye Disease Study.
Ophthalmology. 122:162–9.
5. Chew EY, Klein M, Clemons TE, et al. 2014. No Clinically
Significant Association Between CFH and ARMS2
Genotypes and Response to Nutritional Supplements.
AREDS Report Number 38. Ophthalmology. 121:2173–80.
7. Rosner B. A Review of AREDS Report #38.
10.Fletcher A, Bentham G, et al. 2008. Sunlight Exposure,
Antioxidants, and Age-Related Macular Degeneration,
EUREYE. Arch Ophthalmol. 126(10): 1396-1403.